

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF/2	APPLN. NO. 10/038,591
O I P E S C I T O FEB 07 2003 P A T E N T & T R A D E M A R K O F F I C E		APPLICANT Bruce D. Cohen, et al.	CONFIRMATION NO. 1445
		FILING DATE January 4, 2002	GROUP 1642

RECEIVED

SEARCH CENTER 1600 900

FEB 10 2003

UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,084,085	July 4, 2000	Baserga et al.	536	23.5	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
LH	WO 00/50067	August 31, 2000	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
LH	DiGiovanni, John, et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," <u>Proc. Natl. Acad. Sci. USA</u> , 97:3455-3460 (2000).
	Drexhage, H.A. & Wulffraat, N.M., "Endocrine autoimmune diseases," <u>Netherlands Journal of Medicine</u> , 45:285-293 (1994).
	Kim, Bhumsoo, et al., "Insulin receptor substrate 2 and shc play different roles in insulin-like growth factor I signaling," <u>Journal of Biological Chemistry</u> , 273:34543-34550 (1998).
	Smith, Lois E., et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," <u>Nature Medicine</u> , 5:1390-1395 (1999).
	Tappy, Luc, et al., "Antibodies to insulin-like growth factor I receptors in diabetes and other disorders," <u>Diabetes</u> , 37:1708-1714 (1988).
	Thompson, Kathleen, et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," <u>Pediatric Research</u> , 32:455-459 (1992).
WV	Weightman, David R., et al., "Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy," <u>Autoimmunity</u> , 16:251-257 (1993).
LW	Wright, Christopher, et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," <u>Nature Biotechnology</u> , 18:521-526 (2000).

EXAMINER

DATE CONSIDERED

4/26/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.